

RESIGNATION OF JOINT COMPANY SECRETARY

Melbourne, Australia – 2 December 2024: Percheron Therapeutics Limited (ASX: PER or ‘the Company’), wishes to advise that Ms Alicia Mellors of the Acclime Group has resigned as Joint Company Secretary of the Company.

The Company thanks Ms Mellors for her contribution.

Ms Deborah Ambrosini continues in the role of Chief Financial Officer and Company Secretary and, for the purposes of ASX Listing Rule 12.6, remains the primary person responsible for communication between the Company and the ASX.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in December CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.
